Publication | Open Access
95MO Tinengotinib in patients with advanced, fibroblast growth factor receptor (FGFR) inhibitor refractory/relapsed cholangiocarcinoma
11
Citations
0
References
2023
Year
MedicineBiliary CancerHepatobiliary TumorPathologyFibroblast Growth FactorMolecular OncologyCancer TreatmentOncologyRadiation OncologyCancer ResearchCancer Growth
No additional data available for this publication yet. Check back later!